Conference Coverage

This channel highlights DAIC's coverage of numerous key cardiology and medical imaging conferences each year. These include ACC, AHA, ASE, ASNC, EuroPCR, ECR, HIMSS, HRS, RSNA, SCAI, SCCT, TCT, and VIVA.

News | Heart Valve Technology

Study Finds Sustained Benefit for TAVR vs. SAVR at One Year

October 4, 2019 – A new analysis of the PARTNER 3 Trial data found a modest, but significant, improvement in one-year ...

October 04, 2019

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

News | Heart Failure

Transcatheter Mitral Valve Repair is Cost-Effective in Heart Failure Patients

October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve ...

October 04, 2019

RenalGuard Therapy was found to be superior to the POSEIDON method in preventing contrast-induced acute kidney injury (CI-AKI) for patients with kidney disease who undergo interventional cath lab procedures. Results of the 700 patient, randomized, investigator-driven REMEDIAL III Trial presented at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. #TCT19 #TCT2019

News

Contrast-Induced Kidney Injury Prevented With RenalGuard in REMEDIAL III Trial

October 4, 2019 – RenalGuard Therapy was found to be superior to the POSEIDON method in preventing contrast-induced ...

October 04, 2019

Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent Sapien 3 transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR. #TCT2019

News | Heart Valve Technology

October 3, 2019 – Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and ...

October 03, 2019

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

Feature | Cath Lab

Left Main Treated With PCI or CABG Have Similar Outcomes at Five Years

October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with ...

October 03, 2019

COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

News | Heart Failure

COAPT Three-year Data Show Continued Effectiveness in Heart Failure Patients

October 3, 2019 – The three-year results from the COAPT Trial demonstrated that reducing severe secondary mitral ...

October 03, 2019

The Boston Scientiofic Acurate Neo TAVR valve did not meet non-inferiority to the Sapien 3 valve in patients with severe aortic stenosis. #TAVR #TCT2019

News | Heart Valve Technology

New Acurate neo Self-expanding TAVR Device Does Not Meet Non-Inferiority Compared to Sapien 3

October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate neo ...

October 02, 2019

The Portico FDA investigational device exemption (IDE) study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems. #TAVR #TCT2019

News | Heart Valve Technology

Portico TAVR System Found Safe and Effective for High-Risk Surgical Patients

October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) study found that 30-day safety and one ...

October 02, 2019

News | Stents Drug Eluting

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT

September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug ...

September 30, 2019

News | Stents Drug Eluting

Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD

September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual ...

September 30, 2019

News | Antiplatelet and Anticoagulation Therapies

Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients

September 30, 2019 – Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy ...

September 30, 2019

News | Heart Failure

Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device

September 27, 2019 — Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in ...

September 27, 2019

Technology | Ventricular Assist Devices (VAD)

Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist

September 27, 2019 — Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug ...

September 27, 2019

News | Virtual and Augmented Reality

EchoPixel Introduces 3-D Holographic Intraoperative Software

September 27, 2019 — EchoPixel introduced what it calls the first-ever intraoperative software to provide naked-eye ...

September 27, 2019

Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients

News | Antiplatelet and Anticoagulation Therapies

TWILIGHT Study Shows Ticagrelor Monotherapy Reduces Bleeding Risk Post-PCI in High-Risk Patients

September 26, 2019 — New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy redu ...

September 26, 2019